BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fish and Richardson
Boehringer Ingelheim
Julphar
Baxter
Fuji
Accenture
Colorcon
Merck
Argus Health

Generated: January 19, 2018

DrugPatentWatch Database Preview

Dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir and what is the scope of dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir freedom to operate?

Dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir has five hundred and twenty-one patent family members in fifty-one countries.

One supplier is listed for this compound.
Summary for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
International Patents:521
US Patents:18
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 3,222
Drug Prices:see low prices
DailyMed Link:dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir at DailyMed

US Patents and Regulatory Information for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 ➤ Subscribe ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,394,279 Anti-viral compounds ➤ Subscribe
7,659,405 Polymorph of a pharmaceutical ➤ Subscribe
8,691,878 Solid pharmaceutical dosage form ➤ Subscribe
8,716,454 Solid compositions ➤ Subscribe
9,309,279 Macrocyclic hepatitis C serine protease inhibitors ➤ Subscribe
8,332,661 Method and apparatus for prevention of tampering, unauthorized use, and unauthorized extraction of information from microdevices ➤ Subscribe
9,452,194 Methods for treating HCV ➤ Subscribe
9,676,797 Anti-viral compounds ➤ Subscribe
8,025,899 Solid pharmaceutical dosage form ➤ Subscribe
9,255,092 Polymorph of a pharmaceutical ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

Supplementary Protection Certificates for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2015 Austria ➤ Subscribe PRODUCT NAME: DASABUVIR ODER EIN SALZ DAVON, EINSCHLIESSLICH DASABUVIR-NATRIUM-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/14/983 20150115
2015000039 Germany ➤ Subscribe PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115
0730 Netherlands ➤ Subscribe PRODUCT NAME: PARITAPREVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
2017 00049 Denmark ➤ Subscribe PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728
667 Luxembourg ➤ Subscribe PRODUCT NAME: PARITAPREVIR, OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX). FIRST REGISTRATION: 20150119
0150015 00143 Estonia ➤ Subscribe PRODUCT NAME: DASABUVIIR;REG NO/DATE: EU/1/14/983 19.01.2015
2015 00013 Denmark ➤ Subscribe PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEROF; REG. NO/DATE: EU/1/14/982 20150115
2015 00015 Denmark ➤ Subscribe PRODUCT NAME: OMBITASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/982 20150115
15/010 Ireland ➤ Subscribe PRODUCT NAME: OMBITASVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/982 20150115
0731 Netherlands ➤ Subscribe PRODUCT NAME: OMBITASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Teva
US Department of Justice
Cipla
US Army
Merck
Chubb
McKinsey
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot